Protective Effects of Diuretics Against Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: Systematic Review.

Protective Effects of Diuretics Against Development of Cardiovascular Disease in Patients with Chronic Kidney Disease: Systematic Review. Cardiovasc Hematol Agents Med Chem. 2018 Apr 02;: Authors: Aomatsu A, Ookawara S, Ishibashi K, Morishita Y Abstract Cardiovascular disease is one of the most important risk factors for mortality and morbidity in patients with chronic kidney disease (CKD). This systematic review focuses on the protective effects of diuretics against the development of cardiovascular disease in patients with CKD. Among various kinds of diuretics, spironolactone, a mineralocorticoid receptor antagonist, has been shown to have protective effects against cardiovascular disease in patients with all stages of CKD, including pre-dialysis, hemodialysis, and peritoneal dialysis. Low-dose loop diuretics have also been shown to have cardioprotective effects in patients with CKD during the pre-dialysis and hemodialysis stages; however, high-dose loop diuretics have failed to show these cardioprotective effects. The protective effects of other classes of diuretics, including thiazide and tolvaptan, against cardiovascular diseases in patients with CKD remain unclear. PMID: 29607790 [PubMed - as supplied by publisher]
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research